Arcturus TherapeuticsvsJohnson & Johnson

ARCT and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

ARCT

Arcturus Therapeutics Holdings Inc.

$8.15

Value $232M

+2.31%
ARCT's page

Arcturus Therapeutics (ARCT) has a market value of $232M and Johnson & Johnson (JNJ) $662B. Over the last year, with dividends, ARCT moved +20.6% and JNJ +40.9%. Dividend yield: ARCT none, JNJ 1.92%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ARCT$232M

    JNJ$662B

    JNJ is 2,858 times ARCT

  • Revenue, 12 months

    ARCT$31M

    JNJ$99.3B

    JNJ is 3,255 times ARCT

  • Net income, 12 months

    ARCT-$87M

    JNJ$16.1B

  • Operating margin

    ARCT-311.2%

    JNJ–

  • ROIC

    ARCT-38.7%

    JNJ12.4%

    51.0 points apart

  • P/E

    ARCT–

    JNJ41.2

  • Dividend yield

    ARCT0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    ARCT-77.8%

    JNJ+93.6%

    171.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ARCT-77.8%

JNJ+93.6%

10020020222023202420252026
Returns by period
PeriodARCTWith dividendsJNJWith dividends
1 year since November 17, 2025+20.6%Price +20.6%+40.9%Price +37.8%
3 years since November 17, 2023-67.4%-31.2% a yearPrice -67.4%+99.9%+26.0% a yearPrice +83.6%
5 years since November 17, 2021-77.8%-26.0% a yearPrice -77.8%+93.6%+14.1% a yearPrice +68.4%
10 years since November 18, 2016-42.6%-5.4% a yearPrice -42.6%+210.6%+12.0% a yearPrice +138.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ARCTArcturus TherapeuticsJNJJohnson & Johnson

Valuation

ARCTJNJ
Valuation
Price$8.15$274.88
Market value$232M$662B
Enterprise value (EV)$47M$690B
P/E–41.2
P/E, 5-year median–21.9
P/B1.48.1
EV/EBIT–38.9
Free cash flow yield–3.1%

Results and growth

ARCTJNJ
Results and growth
Revenue, 12 months$31M$99.3B
Net income, 12 months-$87M$16.1B
Free cash flow, 12 months-$63M$20.6B
Earnings per share, 12 months-$3.10$6.59
Revenue growth, year on year-46.1%6.1%
Revenue growth a year, past+53.8%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

ARCTJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin-311.2%–
Net margin-285.9%16.2%
ROIC-38.7%12.4%
ROE-45.0%19.7%

Balance sheet

ARCTJNJ
Balance sheet
Cash$185M$17.2B
Total debt$22M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

ARCTJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ARCT or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Arcturus Therapeutics or Johnson & Johnson?

By market value, Johnson & Johnson ($662B) is about 2,858.2 times Arcturus Therapeutics ($232M), at today's prices.

How did ARCT and JNJ stock do over the last 10 years?

Since November 18, 2016, ARCT's price moved -42.6% and JNJ's +138.4%. With dividends: ARCT -42.6% (-5.4% a year), JNJ +210.6% (+12.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ARCT or JNJ?

The dividend yield at today's price is none for Arcturus Therapeutics and 1.92% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Arcturus Therapeutics or Johnson & Johnson?

Over the last twelve months, the net margin was -285.9% for Arcturus Therapeutics and 16.2% for Johnson & Johnson, and the operating margin -311.2% and –. Revenue was $31M and $99.3B.

Which is the better investment, Arcturus Therapeutics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.